Chemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer

Author(s): Jun Zhou*, Zhaopei Li*, Jun Li, Binbin Gao, Wei Song

Journal Name: Current Molecular Medicine

Volume 19 , Issue 3 , 2019


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

The malignancy of small cell lung cancer (SCLC) is the highest amongst all lung cancer types. It is characterized by rapid growth, early occurrence of distant sites metastasis, poor survival rates and is initially sensitive to chemotherapy and radiotherapy. However, most patients eventually relapse or disease progresses because of chemotherapy resistance. Because of lack of effective second-line therapies, the prognosis of SCLC patients is usually poor. For the development of novel therapies, it is necessary to understand the mechanisms of chemotherapy resistance in SCLC. The mechanism is complex, because multiple factors could lead to chemotherapy resistance. An overview of multiple events triggering the formation of chemotherapy resistance phenotypes of SCLC cells is discussed.

Keywords: Small cell lung cancer, chemotherapy resistance, multidrug resistance, intracellular enzyme system, apoptosis escape, cell repair system, cancer stem cells.

[1]
Rodriguez E, Lilenbaum RC. Small cell lung cancer: past present and future. Curr D Oncol Rep 2010; 12: 327-34.
[2]
Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366: 1385-96.
[3]
Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 2006; 207: 571-81.
[4]
Chen YT, Feng B, Chen LB. Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev 2012; 13: 3577-81.
[5]
Bradley G1, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13: 223-33.
[6]
Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-9.
[7]
Brock I, Hipfner DR, Nielsen BS, et al. Sequential coexpression of the multidrug resistance gene MRP and mdr1 and their products in VP-16 (Etoposide)-selected H69 small cell lung cancer cells. Cancer Res 1995; 55: 459-62.
[8]
Narasaki F, Matsuo I, Ikuno N, Fukuda M, Soda H, Oka M. Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Anticancer Res 1996; 16: 2079-82.
[9]
Sohn JW, Lee SY, Lee SJ, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006; 36: 137-41.
[10]
Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC, Liang JA. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 2005; 183: 177-83.
[11]
Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010; 46: 1692-702.
[12]
Izquierdo MA, Shoemaker RH, Flens MJ, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996; 65: 230-7.
[13]
Triller N, Korosec P, Kern I, Kosnik M, Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006; 54: 235-40.
[14]
Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res 2005; 65: 991-8.
[15]
Awasthi YC, Sharma R, Yadav S, Dwivedi S, Sharma A, Awasthi S. The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. Curr Drug Metab 2007; 8: 315-23.
[16]
Haixia P, Yifeng B, Honglin H. Role and clinical significance of RLIP76 in regulation of multi-drug resistance of small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2015; 37: 266-71.
[17]
Sun C, Lan P, Han Q, et al. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun 2018; 9: 1241-57.
[18]
Liu H, Bai Y, Wang W, Guo L. Role of SALL4 in regulating multi-drug resistance of small cell lung cancer and its clinical significance. Zhonghua Bing Li Xue Za Zhi 2014; 43: 604-8.
[19]
Yang L, Hu H, Deng Y, Bai Y. Role of SPHK1 regulates multi-drug resistance of small cell lung cancer and its clinical significance. Zhongguo Fei Ai Za Zhi 2014; 17: 769-77.
[20]
Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010; 75: 173-234.
[21]
Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, Giaccone G. Expression of DNA topoisomerase II alpha and topoisomerase II beta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999; 5: 2048-58.
[22]
Ceppi P, Longo M, Volante M, et al. Excision repair cross complementing-1 and topoisomerase II alpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 2008; 3: 583-9.
[23]
Lawson MH, Cummings NM, Rassl DM, et al. Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res 2011; 71: 4877-87.
[24]
Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
[25]
Hodkinson PS, Mackinnon AC, Sethie T. Extracellular matrix regulation of drug resistance in small-cell lung. Int J Radiat Biol 2007; 83: 733-41.
[26]
Kohmo S, Kijima T, Otani Y, et al. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 2010; 70: 8025-35.
[27]
Lane DP. Cancer: p53, guardian of the genome. Nature 1992; 358: 15-6.
[28]
Liu X, Lin XJ, Wang CP, et al. Association between smoking and p53 mutation in lung cancer: a meta-analysis. Clin Oncol (R Coll Radiol) 2014; 26: 18-24.
[29]
Gemba K, Ueoka H, Kiura K, Tabata M, Harada M. Immunohistochemical detection of mutant p53 protein in small cell lung cancer: relationship to treatment outcome. Lung Cancer 2000; 29: 23-31.
[30]
Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinoma: evidence of p53- independent expression and association with tumoral differentiation. Oncogene 1996; 12: 1319-24.
[31]
Yoshida K, Miki Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci 2010; 101: 831-5.
[32]
Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-92.
[33]
Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anticancer agents (MMC, CPT-11, ADM) is inhibited by BCL-2. Biochem Biophys Res Commun 1993; 192: 30-6.
[34]
Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-81.
[35]
Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2 in small cell lung cancer. Cancer Res 2008; 68: 2321-8.
[36]
Rudin CM, Kozloff M, Hoffman PC, et al. Phase I study of G3139, a BCL-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22: 1110-7.
[37]
Vilborg A, Bersani C, Wilhelm MT, Wiman KG. The p53 target Wig-1: a regulator of mRNA stability and stem cell fate. Cell Death Differ 2011; 18: 1434-40.
[38]
Bersani C, Xu LD, Vilborg A, Lui WO, Wiman KG. Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3σ. Oncogene 2014; 33: 4407-17.
[39]
Luo S, Bai Y, Lan H. Influence of interference of WIG-1 on the multi-drug resistance in small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2014; 36: 733-8.
[40]
Wilson MA. The role of cysteine oxidation in DJ‐1 function and dysfunction. Antioxid Redox Signal 2011; 15: 111-22.
[41]
MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug‐induced apoptosis in non‐small cell lung carcinoma: identification of RS/DJ‐1 and RhoGDIalpha. Cancer Res 2003; 63: 6928-34.
[42]
Bindukumar B, Schwartz S, Aalinkeel R, Mahajan S, Lieberman A, Chadha K. Proteomic profiling of the effect of prostate‐specific antigen on prostate cancer cells. Prostate 2008; 68: 1531-45.
[43]
Davidson B, Hadar R, Schlossberg A, et al. Expression and clinical role of DJ‐1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol 2008; 39: 87-95.
[44]
Tsuchiya B, Iwaya K, Kohno N, et al. Clinical significance of DJ‐1 as a secretory molecule: retrospective study of DJ‐1 expression at mRNA and protein levels in ductal carcinoma of the breast. Histopathology 2012; 61: 69-77.
[45]
Shu K, Xiao Z, Long S, et al. Expression of DJ‐1 in endometrial cancer: close correlation with clinicopathological features and apoptosis. Int J Gynecol Cancer 2013; 23: 1029-35.
[46]
Cao J, Lou S, Ying M, Yang B. DJ‐1 as a human oncogene and potential therapeutic target. Biochem Pharmacol 2015; 93: 241-50.
[47]
Chen Y, Kang M, Lu W, et al. DJ‐1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. J Cancer Res Clin Oncol 2012; 138: 1463-74.
[48]
Zeng HZ, Qu YQ, Zhang WJ, Xiu B, Deng AM, Liang AB. Proteomic analysis identified DJ‐1 as a cisplatin resistant marker in non‐small cell lung cancer. Int J Mol Sci 2011; 12: 3489-99.
[49]
Liu H, Wang M, Li M, et al. Expression and role of DJ‐1 in leukemia. Biochem Biophys Res Commun 2008; 375: 477-83.
[50]
Gao H, Niu Y, Li M, Fang S, Guo L. Identification of DJ‐1 as a contributor to multidrug resistance in human small‐cell lung cancer using proteomic analysis. Int J Exp Pathol 2017; 98: 67-74.
[51]
Guo L, Zhou Y, Sun Y, Zhang F. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. Eur J Cancer 2010; 46: 636-41.
[52]
Henrion M, Frampton M, Scelo G, et al. Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. Hum Mol Genet 2013; 22: 825-31.
[53]
Lee JY, Park MK, Park JH, et al. Loss of the polycomb protein Mel-18 enhances the epithelial–mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 2014; 33: 1325-35.
[54]
Nam EH, Lee Y, Park YK, Lee JW, Kim S. ZEB2 upregulates integrin alpha5 expression through cooperation with Sp1 to induce invasion during epithelial–mesenchymal transition of human cancer cells. Carcinogenesis 2012; 33: 563-71.
[55]
Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett 2014; 344: 166-73.
[56]
Fang S, Zeng X, Zhu W, Tang R, Chao Y, Guo L. Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer. Exp Mol Pathol 2014; 96: 438-44.
[57]
Hansen LT, Thykjaer T, Ørntoft TF, et al. The role of mismatch repair in small-cell lung cancer cells. Eur J Cancer 2003; 39: 1456-67.
[58]
Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000; 20: 645-52.
[59]
Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-16.
[60]
Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-304.
[61]
Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11: 2215-21.
[62]
Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-91.
[63]
Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-25.
[64]
Lee HW, Han JH, Kim JH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008; 59: 95-104.
[65]
Kim YH, Ishii G, Goto K, et al. Expression of breast cancer resistance protein is associated with poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 2009; 65: 105-11.
[66]
Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung. J Thorac Oncol 2010; 5: 453-9.
[67]
Tao H, Zhang Y, Li Q, Chen J. Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review. J Cancer Res Clin Oncol 2017; 143: 2245-56.
[68]
Sarvi S, Mackinnon AC, Avlonitis N, et al. CD133t cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res 2014; 74: 1554-65.
[69]
Yu J, Wang S, Zhao W, et al. Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel α2δ1 subunit-mediated chemotherapy resistance in small-cell lung cancer. Clin Cancer Res 2018; 24: 2148-58.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [157 - 163]
Pages: 7
DOI: 10.2174/1566524019666190226104909
Price: $65

Article Metrics

PDF: 35
HTML: 13
EPUB: 1